SBFM · Sunshine Biopharma Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SBFM
this stock
Sunshine Biopharma Inc.
|
$3.27M | — | +4.1% | — | 0.6% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.2% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +27.1% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -12.8% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 2.1%
- Net QoQ
- +44.4K sh
- Top holder
- HRT FINANCIAL LP
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SBFM | -48.6% | -63.2% | -95.7% | -45.7% | -96.6% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -49.8% | -63.8% | -107.2% | -47.3% | -110.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.